

## **REMARKS**

In the specification, a paragraph was added to claim priority to International Patent Application No. PCT/EP03/050928, filed December 2, 2003, and European Patent Application No. 02080054.6, filed December 3, 2002. Also the sequence listing from the PCT Application has been replaced with a sequence listing that meets U.S. requirements. In particular, the sequence listing has been corrected to show the individual inventors and list the foreign priority for the application. Paper and electronic copies of the replacement sequence listing are attached.

### **Sequence Statement in compliance with 37 C.F.R. 1.821(f)**

The sequence listing recorded in computer readable form is identical to the paper copy of the sequence listing.


Claims 19 and 21 were canceled. New claims 23-29 were added. Claims 1-18, 20 and 22 were amended. In particular, the claims were amended to provide correct antecedents, remove any multiple dependencies, and clarify that all claimed polynucleotides are distinguished from naturally occurring sequences in that they are "recombinant". "Recombinant" is a term defined in the paragraph bridging pages 5 and 6 of the specification. Claims 1-18, 20 and 22-29 are pending.

No new matter has been entered by these amendments.

Applicants respectfully request the issuance of a timely Notice of Allowance in the case.

Akzo Nobel Inc.  
Intellectual Property Dept.  
7 Livingstone Avenue  
Dobbs Ferry, NY 10522-3408  
(914) 674-5459

Respectfully submitted

  
Michelle J. Burke  
Attorney for Applicants  
Registration No.: 37,791